Abeona Therapeutics Inc.(NASDAQ: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene and cell therapies for life-threatening rare ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

Regenxbio (RGNX) Misses Q3 EPS by 12c, Revenues MissNovember 7, 2018 5:08 PM Abeona Therapeutics and REGENXBIO Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 VectorNovember 5, 2018 7:00 AM